In vitro bioactivity, cytocompatibility, and antibiotic release profile of gentamicin sulfate-loaded borate bioactive glass/chitosan composites

Journal of Materials Science: Materials in Medicine

Volumn 24, Issue 10, 2013, Pages 2391-2403

  Cui, Xu ^a   Gu, Yifei ^a   Li, Le ^a   Wang, Hui ^a   Xie, Zhongping ^b   Luo, Shihua ^b   Zhou, Nai ^a   Huang, Wenhai ^a   Rahaman, Mohamed N ^c  

^a TONGJI UNIVERSITY   (China)

^b SHANGHAI JIAO TONG UNIVERSITY   (China)

^c University of Missouri Rolla   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE ACTIVITY; ANTIBIOTIC RELEASE; CYTOCOMPATIBILITY; GENTAMICIN SULFATES; GLASS-BASED COMPOSITES; IN-VITRO BIOACTIVITY; PHOSPHATE-BUFFERED SALINES; SUSTAINED RELEASE;

ANTIBIOTICS; BIOACTIVE GLASS; CELL PROLIFERATION; CHITOSAN; COMPRESSIVE STRENGTH; PHOSPHATASES;

SULFUR COMPOUNDS;

ALKALINE PHOSPHATASE; BORIC ACID; CHITOSAN; DRUG CARRIER; GENTAMICIN; GLASS; HYDROXYAPATITE; PHOSPHATE BUFFERED SALINE;

ANTIBACTERIAL ACTIVITY; ARTICLE; BIOCOMPATIBILITY; BIODEGRADATION; BONE DEVELOPMENT; BONE REGENERATION; CELL ADHESION; CELL PROLIFERATION; COMPOSITE MATERIAL; COMPRESSIVE STRENGTH; CONTROLLED STUDY; CYTOCOMPATIBILITY; ENZYME ACTIVITY; IMMERSION; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS; SUSTAINED DRUG RELEASE;

3T3 CELLS; ALKALINE PHOSPHATASE; ANIMALS; ANTI-BACTERIAL AGENTS; BIOCOMPATIBLE MATERIALS; BONE AND BONES; BORATES; CELL ADHESION; CHITOSAN; COMPRESSIVE STRENGTH; DRUG DELIVERY SYSTEMS; DURAPATITE; GENTAMICINS; GLASS; IONS; MATERIALS TESTING; MICE; MICROSCOPY, ELECTRON, SCANNING; OSTEOGENESIS; PRESSURE; SPECTROSCOPY, FOURIER TRANSFORM INFRARED; TIME FACTORS;

EID: 84885178662     PISSN: 09574530     EISSN: 15734838     Source Type: Journal    
DOI: 10.1007/s10856-013-4996-0     Document Type: Article

References (45)

1. Xie ZP, Liu X, Huang WH, et al. Treatment of osteomyelitis and repair of bone defect by degradable bioactive borate. J Controlled Release. 2009;139:118-26.
2. Bucholz HW, Heinet K, Foerster GW. Infected prostheses: the role of antibiotic cement. In: D'Ambrosia RD, Marier RL, editors. Orthopaedic infections. New Jersey: Slack Inc; 1989. p. 477-88.
3. Zhao L, Yan X, Yu C, et al. Mesoporous bioactive glasses for controlled drug release. Microporous Mesoporous Mater. 2008;109:210-5.
4. Xue JM, Shi M. PLGA/Mesoporous silica hybrid structure for controlled drug release. J Controlled Release. 2004;98:209-17.
5. Xia W, Chang J. Well-ordered mesoporous bioactive glasses (MBG): a promising bioactive drug delivery system. J Controlled Release. 2006;110:522-30.
6. Jain AK, Panchagnula R. Skeletal drug delivery systems. Int J Pharm. 2000;206:1-12.
7. Lee CH, Singla A, Lee Y. Biomedical applications of collagen. Int J Pharm. 2001;221:1-22.
8. Saito K, Hoshino T. Apatite-coated solid composition. US Patent 6344209, 2002.
9. Liu X, Xie ZP, Huang WH, et al. Bioactive borate glass scaffolds: in vitro and in vivo evaluation for use as a drug delivery system in the treatment of bone infection. J Mater Sci Mater Med. 2010;21:575-82.
10. Zhang X, Jia WJ, Huang WH, et al. Teicoplanin-loaded borate bioactive glass implants for treating chronic bone infection in a rabbit tibia osteomyelitis model. Biomaterials. 2010;31(22):5865-74.
11. Rahaman MN, Day DE, Fu Q, et al. Bioactive glass in tissue engineering. Acta Biomater. 2011;7:2355-73.
12. Fu Q, Saiz E, Rahaman MN, et al. Bioactive glass scaffolds for bone tissue engineering: state of the art and future perspectives. Mater Sci Eng C. 2011;31:1245-56.
13. Rahaman MN, Brown RF, Day DE, et al. Bioactive glasses for non-bearing applications in total joint replacement. Semin Arthroplasty. 2007;17:102-12.
14. Liang W, Rahaman MN, Day DE, et al. Bioactive borate glass scaffold for bone tissue engineering. J Non-Cryst Solids. 2008;354:1690-6.
15. Huang TS, Rahaman MN, Day ED, et al. Porous and strong bioactive glass (13-93) scaffolds fabricated by freeze extrusion technique. Mater Sci Eng C. 2011;31:1482-9.
16. Domingues ZR, Cortés ME, Gomes TA, et al. Bioactive glass as a drug delivery system of tetracycline and tetracycline associated with β-cyclodextrin. Biomaterials. 2004;25:327-33.
17. Jia WT, Zhang X, Huang WH, et al. Novel borate glass chitosan composite as a delivery vehicle for teicoplanin in the treatment of chronic osteomyelitis. Acta Biomater. 2010;6:812-9.
18. Yao AH, Wang D, Huang WH, et al. In vitro bioactive characteristics of borate-based glasses with controllable degradation behavior. J Am Ceram Soc. 2007;90(1):303-6.
19. Liu X, Huang WH, Fu HL, et al. Bioactive borosilicate glass scaffolds: in vitro degradation and bioactivity behaviors. J Mater Sci Mater Med. 2009;20:1237-43.
20. Brown RF, Day DE, Rahaman MN, et al. Growth and differentiation of osteoblastic cells on 13-93 bioactive glass fibers and scaffolds. Acta Biomater. 2008;4:387-96.
21. Huang WH, Rahaman MN, Day DE, et al. Mechanisms for converting bioactive silicate, borate, and borosilicate glasses to hydroxyapatite in dilute phosphate solutions. Phys Chem Glasses. 2006;47(6):647-58.
22. Huang WH, Day DE, Rahaman MN, et al. Kinetics and mechanisms of the conversion of silicate (45S5), borate, and borosilicate glasses to hydroxyapatite in dilute phosphate solutions. J Mater Sci Mater Med. 2006;17:583-96.
23. Fu Q, Rahaman MN, Fu HL, et al. Silicate, borosilicate, and borate bioactive glass scaffolds with controllable degradation rate for bone tissue engineering applications. I. Preparation and in vitro degradation. J Biomed Mater Res Part A. 2011;95(1):164-71.
24. Fu Q, Rahaman MN, Bal BS, et al. Silicate, borosilicate, and borate bioactive glass scaffolds with controllable degradation rate for bone tissue engineering applications. II. In vitro and in vivo biological evaluation. J Biomed Mater Res Part A. 2011;95(1):172-9.
25. Majeti NV, Ravi K. A review of chitin and chitosan applications. React Funct Polym. 2000;46:1-27.
26. Frutos P, Diez-Peña E, Frutos G, et al. Release of gentamicin sulphate from a modified commercial bone cement. Effect of (2-hydroxyethyl methacrylate) comonomer and poly(N-vinyl-2-pyrrolidone) additive on release mechanism and kinetics. Biomaterials. 2002;23:3787-97.
27. Clarot I, Chaimbault P, Hasdenteufel F, et al. Determination of gentamicin sulfate and related compounds by high-performance liquid chromatography with evaporative light scattering detection. J Chromatogr A. 2004;1031:281-7.
28. Lowy FD. Staphylococcus aureus infections. N Engl J Med. 1998;339:520-32.
29. Boyle VJ, Fancher ME. Ross Jr R W. Rapid, modified Kirby-Bauer susceptibility test with single, high-concentration antimicrobial disks. Antimicrob Agents Chemother. 1973;3:418-24.
30. Ning J, Wang DP, Huang WH, et al. Preparation of borosilicate glass and their bioactivity and biodegradation in vitro. J Chin Ceram Soc. 2006;34(11):1326-30.
31. Zhang X, Fu HL, Huang WH, et al. In vitro bioactivity and cytocompatibility of porous scaffolds of bioactive borosilicate glasses. Chin Sci Bull. 2009;54(24):463-8.
32. Maeda H, Ishida EH, Kasuga T. Hydrothermal preparation of tobermorite incorporating phosphate species. Mater Lett. 2012;68:382-4.
33. Kokubo T, Kim HM, Kawashita M. Novel bioactive materials with different mechanical properties. Biomaterials. 2003;24:2161-75.
34. Goldstein SA. The mechanical properties of trabecular bone: dependence on anatomic location and function. J Biomech. 1987;20:1055-61.
35. Doadrio JC, Arcos D, Vallet-Regí M, et al. Calcium sulphate-based cements containing cephalexin. Biomaterials. 2004;25:2629-35.
36. Phaechamud T, Charoenteeraboon J. Antibacterial activity and drug release of chitosan sponge containing doxycycline hyclate. AAPS Pharm Sci Tech. 2008;9:829-35.
37. Zhang Y, Zhang M. Calcium phosphate/chitosan composite scaffolds for controlled in vitro antibiotic drug release. J Biomed Mater Res. 2002;62:378-86.
38. Hunt CD. One possible role of dietary boron in higher animals and humans. Biol Trace Elem Res. 1998;66:205-25.
39. Ying X, Cheng S, Peng L, et al. Effect of boron on osteogenic differentiation of human bone marrow stromal cells. Biol Trace Elem Res. 2011;144:306-15.
40. Devirian TA, Volpe SL. The physiological effects of dietary boron. Crit Rev Food Sci Nutr. 2003;43(2):219-31.
41. Brown RF, Rahaman MN, Huang WH, et al. Effect of to borate glass composition on its conversion hydroxyapatite and on the proliferation of MC3T3-E1 cells. J Biomed Mater Res Part A. 2008;88:392-400.
42. Benderdour M, Bui-Van T, Dicko A, et al. In vivo and vitro effects of boron and boronated compounds. J Trace Elem Med Biol. 1998;12(1):2-7.
43. Murray FJ. A human health risk assessment of boron (boric acid and borax) in drinking water, biochemical and physiologic consequences of boron deprivation in humans. Regul Toxicol Pharmacol. 1995;22:221-30.
44. Forrest HN. Boron in human and animal nutrition. Plant Soil. 1997;193:199-208.
45. Murray FJ. A comparative review of the pharmacokinetics of boric acid in rodents and humans. Biol Trace Elem Res. 1998;66:331-9.